Aidoc, a global pioneer in clinical AI solutions, has expanded its partnership with Integral Diagnostics (IDX), the leading provider of AI-driven medical imaging services, across Australia and New Zealand.
This enhanced collaboration, which started four years ago, leverages Aidocs aiOS platform to alert radiologists and care teams to suspected and unsuspected critical findings in medical images.
Since 2019, Aidoc has processed over 600,000 cases across IDX’s entire network – including its partner facilities and hospitals.
Looking ahead, significant advancements are on the horizon. Starting July 2025, the Australian Government will fund the National Lung Cancer Screening Programme (NLCSP), a crucial step in early detection of lung cancer. IDX is currently trialling a new algorithm within Aidoc’s aiOS platform designed to notify radiologists of lung nodules and measure them accurately, enabling earlier and appropriate intervention for lung cancer.
“Aidoc’s AI has significantly improved patient care and service. We’re keen to test and use their Chest CT AI algorithms to automate our reviews in the National Lung Cancer Screening Programme to enable us to detect disease earlier, more accurately and more efficiently”, said Dr. Ian Kadish, CEO and Managing Director at Integral Diagnostics.
Rotem Geslevich, Senior Director of Business Development, Aidoc, said: “Our partnership with Integral Diagnostics underscores our commitment to driving better health outcomes. As the Lung Cancer Screening initiative approaches, we are excited to play a pivotal role in saving lives.”
